These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 30539338)

  • 1. Changes in serum and intracardiac fibroblast growth factor 23 during the progression of left ventricular hypertrophy in hypertensive model rats.
    Fujii H; Watanabe K; Kono K; Goto S; Watanabe S; Nishi S
    Clin Exp Nephrol; 2019 May; 23(5):589-596. PubMed ID: 30539338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploring the implications of blocking renin-angiotensin-aldosterone system and fibroblast growth factor 23 in early left ventricular hypertrophy without chronic kidney disease.
    Watanabe K; Fujii H; Okamoto K; Kono K; Goto S; Nishi S
    Front Endocrinol (Lausanne); 2023; 14():1276664. PubMed ID: 38174329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [PPAR alpha activator fenofibrate regressed left ventricular hypertrophy and increased myocardium PPAR alpha expression in spontaneously hypertensive rats].
    Chen HJ; Chen JZ; Wang XX; Yu M
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2007 Sep; 36(5):470-6. PubMed ID: 17924466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibroblast growth factor 23: a possible cause of left ventricular hypertrophy in hemodialysis patients.
    Hsu HJ; Wu MS
    Am J Med Sci; 2009 Feb; 337(2):116-22. PubMed ID: 19214027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiac hypertrophy elevates serum levels of fibroblast growth factor 23.
    Matsui I; Oka T; Kusunoki Y; Mori D; Hashimoto N; Matsumoto A; Shimada K; Yamaguchi S; Kubota K; Yonemoto S; Higo T; Sakaguchi Y; Takabatake Y; Hamano T; Isaka Y
    Kidney Int; 2018 Jul; 94(1):60-71. PubMed ID: 29751971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Upregulation of ligand, receptor system, and amidating activity of adrenomedullin in left ventricular hypertrophy of severely hypertensive rats: effects of angiotensin-converting enzyme inhibitors and diuretic.
    Wang X; Nishikimi T; Akimoto K; Tadokoro K; Mori Y; Minamino N
    J Hypertens; 2003 Jun; 21(6):1171-81. PubMed ID: 12777955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heart-bound adiponectin, not serum adiponectin, inversely correlates with cardiac hypertrophy in stroke-prone spontaneously hypertensive rats.
    Inoue T; Takemori K; Mizuguchi N; Kimura M; Chikugo T; Hagiyama M; Yoneshige A; Mori T; Maenishi O; Kometani T; Itoh T; Satou T; Ito A
    Exp Physiol; 2017 Nov; 102(11):1435-1447. PubMed ID: 28841247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atorvastatin prevents connexin43 remodeling in hypertrophied left ventricular myocardium of spontaneously hypertensive rats.
    Chen HJ; Yao L; Chen TG; Yu M; Wang LH; Chen JZ
    Chin Med J (Engl); 2007 Nov; 120(21):1902-7. PubMed ID: 18067764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of etelcalcetide on cardiac hypertrophy in hemodialysis patients: a randomized controlled trial (ETECAR-HD).
    Dörr K; Kammer M; Reindl-Schwaighofer R; Lorenz M; Loewe C; Marculescu R; Erben R; Oberbauer R
    Trials; 2019 Oct; 20(1):601. PubMed ID: 31651370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antihypertensive agents that limit ventricular hypertrophy inhibit cardiac expression of insulin-like growth factor-I.
    Donohue TJ; Dworkin LD; Ma J; Lango MN; Catanese VM
    J Investig Med; 1997 Dec; 45(9):584-91. PubMed ID: 9444886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of cardiac FGF23/FGFR4 expression is associated with left ventricular hypertrophy in patients with chronic kidney disease.
    Leifheit-Nestler M; Große Siemer R; Flasbart K; Richter B; Kirchhoff F; Ziegler WH; Klintschar M; Becker JU; Erbersdobler A; Aufricht C; Seeman T; Fischer DC; Faul C; Haffner D
    Nephrol Dial Transplant; 2016 Jul; 31(7):1088-99. PubMed ID: 26681731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advanced hypertensive heart disease in spontaneously hypertensive rats. Lisinopril-mediated regression of myocardial fibrosis.
    Brilla CG; Matsubara L; Weber KT
    Hypertension; 1996 Aug; 28(2):269-75. PubMed ID: 8707393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes of FGF23 and the Renin-Angiotensin-System in Male Mouse Models of Chronic Kidney Disease and Cardiac Hypertrophy.
    Okamoto K; Fujii H; Watanabe K; Goto S; Kono K; Nishi S
    J Endocr Soc; 2022 Feb; 6(2):bvab187. PubMed ID: 35047715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Associations between fibroblast growth factor 23 and cardiac characteristics in pediatric heart failure.
    Isakova T; Houston J; Santacruz L; Schiavenato E; Somarriba G; Harmon WG; Lipshultz SE; Miller TL; Rusconi PG
    Pediatr Nephrol; 2013 Oct; 28(10):2035-42. PubMed ID: 23740037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Salvia miltiorrhiza on left ventricular hypertrophy and cardiac aldosterone in spontaneously hypertensive rats.
    Han S; Zheng Z; Ren D
    J Huazhong Univ Sci Technolog Med Sci; 2002; 22(4):302-4. PubMed ID: 12674764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fibroblast growth factor 23, left ventricular mass, and left ventricular hypertrophy in community-dwelling older adults.
    Jovanovich A; Ix JH; Gottdiener J; McFann K; Katz R; Kestenbaum B; de Boer IH; Sarnak M; Shlipak MG; Mukamal KJ; Siscovick D; Chonchol M
    Atherosclerosis; 2013 Nov; 231(1):114-9. PubMed ID: 24125420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of salvia miltiorrhiza Bge on left ventricular hypertrophy and the expression of tumor necrosis factor-alpha in spontaneously hypertensive rats.
    Sun L; Zheng Z
    J Huazhong Univ Sci Technolog Med Sci; 2007 Jun; 27(3):245-7. PubMed ID: 17641833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patients with FGF23-related hypophosphatemic rickets/osteomalacia do not present with left ventricular hypertrophy.
    Takashi Y; Kinoshita Y; Hori M; Ito N; Taguchi M; Fukumoto S
    Endocr Res; 2017 May; 42(2):132-137. PubMed ID: 27754732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased Circulating FGF23 Does Not Lead to Cardiac Hypertrophy in the Male Hyp Mouse Model of XLH.
    Liu ES; Thoonen R; Petit E; Yu B; Buys ES; Scherrer-Crosbie M; Demay MB
    Endocrinology; 2018 May; 159(5):2165-2172. PubMed ID: 29635291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of medium-chain triglyceride (MCT) application to SHR on cardiac function, hypertrophy and expression of endothelin-1 mRNA and other genes.
    Shimojo N; Miyauchi T; Iemitsu M; Irukayama-Tomobe Y; Maeda S; Ohkubo T; Tanaka Y; Goto K; Yamaguchi I
    J Cardiovasc Pharmacol; 2004 Nov; 44 Suppl 1():S181-5. PubMed ID: 15838274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.